Pharmacology, efficacy and safety of oral phosphate binders
- 6 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 7 (10), 578-589
- https://doi.org/10.1038/nrneph.2011.112
Abstract
The ideal serum level of phosphate in patients on dialysis, and the benefits of controlling levels of phosphate in serum remain unclear despite observational studies that associate phosphate levels with mortality. In the absence of robust data from trials, current guidelines are necessarily based on opinion. Oral phosphate binders are required by the majority of patients on dialysis, and all of these binders can control serum levels of phosphate to similar degrees. Patient preference and adherence to prescribed therapy is at least as important as the efficacy of the prescribed binder. Avoidance of calcium-containing binders has become accepted practice where the alternatives are affordable, but incontrovertible evidence in favor of this approach is lacking. Use of sevelamer and lanthanum avoids calcium loading, but at considerable financial cost and with no reliable patient outcome data to prove their value. Additional approaches to aid control of serum levels of phosphate include blockade of gastrointestinal phosphate absorption and possibly binding of salivary phosphate. Importantly, the role of phosphate control in determining patient outcomes must be quantified, which is likely to require a large randomized, controlled study of two levels of phosphate control. Without such a study we will continue to rely on observational data with all its uncertainties and potential to mislead.Keywords
This publication has 120 references indexed in Scilit:
- The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriolNephrology Dialysis Transplantation, 2010
- Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabilityNephrology Dialysis Transplantation, 2010
- Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticumJournal of Molecular Medicine, 2010
- Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled TrialsAmerican Journal of Kidney Diseases, 2009
- A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysisNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23: A Possible Cause of Left Ventricular Hypertrophy in Hemodialysis PatientsThe American Journal of the Medical Sciences, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burdenNephrology Dialysis Transplantation, 2008
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007
- Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administrationKidney International, 2005